Track topics on Twitter Track topics that are important to you
KOL Perspectives: BTK Inhibitors in RA
This KOL Insight briefing focuses on KOLs views of BTK Inhibitors in RA.
Awareness and potential of BTK inhibitors in RA
Perceptions of BMS986142's Phase IItrial design
Impact of poseltinib discontinuation on existing perception of BTK inhibitors in RA
Of the named BTK inhibitors, KOLs demonstrated the greatest awareness of BMS986142, despite its lack of Phase II data
KOLs were divided over BMS986142's ability to achieve ACR70 by Week 12 in a refractory patient population
For the majority of KOLs, poseltinib's discontinuation had little to no impact on their existing perception of BTK inhibitors in RA.
The insight briefing is based on Sociable Pharma's analysis of primary research with our RA key opinion leaders KOLs.
In total, we conducted interviews with 10 KOLs
5 Europebased 5 N. Americabased
Interviews performed during Q2 2018
KOL data is analyzed to produce
Charts summarizing KOL opinions
Chart callouts of key information details
Summary of KOL reporting trends
Insight from Sociable Pharma's analysts
Reasons to buy
Combines Qualitative semiquantitative insight from key opinion leaders on BTK Inhibitors in RA
Includes insight recommendations from our diseasespecific healthcare analysts
Utilizes independent expert viewpoints to validate the impact of new clinical data emerging trends on management of RA
Provides costeffective support for your advisory boards, with topics acting as a catalyst for further expert discussion.NEXT ARTICLE
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...